Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 5903.102 | uM | inf | 0.01035 | 0.7898 | 0.7837 | 0.8245 | 0.0669 | 0.9137 | 1.2557 | |
BT-20 | TNBC | Basal A | Ribavirin | 15385.211 | uM | inf | inf | 0.4315 | 0.4315 | 0.0000 | 0.1628 | 0.4682 | 0.7321 | |||
21MT-1 | HER2amp | - | MG-132 | Proteasome | Proteasome | 14191.189 | uM | inf | inf | -0.1161 | -0.1161 | 0.0000 | 0.5482 | 0.5418 | 2.9704 | |
21MT-1 | HER2amp | - | MG-132 | Proteasome | Proteasome | 14191.189 | uM | inf | inf | -0.1161 | -0.1161 | 0.0000 | 0.5482 | 0.5418 | 2.9704 | |
600MPE | HR+ | Luminal | XRP44X | ELK3 | MAPK | 12224.157 | uM | inf | 0.72241 | 0.7069 | 0.6798 | 1.3565 | 0.1569 | 0.6341 | 1.0737 | |
184A1 | NM | Basal | (Z)-4-Hydroxytamoxifen | ESR1 | 9047.132 | uM | inf | inf | 0.4055 | 0.4055 | 0.0000 | 0.2074 | 0.3073 | 0.6985 | ||
AU565 | HER2amp | Luminal | AG1024 | IGF1R | RTK | 5900.066 | uM | inf | 6.12470 | 0.8829 | 0.8829 | 4.9899 | 0.0099 | 0.8759 | 2.7232 | |
BT-474 | HER2amp | Luminal | Gemcitabine | DNA replication | DNA replication | 9163.03 | uM | inf | inf | -0.5674 | -0.5674 | 0.0000 | 0.6950 | 0.4965 | 0.3535 | |
BT-20 | TNBC | Basal A | PD184352 | MEK | MAPK | 10581.146 | uM | inf | inf | 0.7166 | 0.7166 | 0.0000 | 0.1279 | 0.5419 | 1.1650 | |
600MPE | HR+ | Luminal | Nilotinib | ABL | nRTK | 12224.145 | uM | inf | inf | 0.9894 | 0.9894 | 0.0000 | -0.0249 | -0.6099 | 0.9737 | |
184A1 | NM | Basal | ZM-447439 | AURK | AURK | 12509.169 | uM | inf | 1.20210 | 0.5422 | 0.5277 | 0.9240 | 0.1592 | 0.9369 | 1.5064 | |
AU565 | HER2amp | Luminal | FTase Inhibitor I | Ftase | MAPK | 10880.154 | uM | inf | inf | 0.9251 | 0.9251 | 0.0000 | 0.0449 | -0.1660 | 1.7853 | |
AU565 | HER2amp | Luminal | PS-1145 | IKK | NFKB | 5901.065 | uM | inf | inf | 0.9807 | 0.9807 | 0.0000 | 0.0027 | -0.0002 | 2.0114 | |
BT-20 | TNBC | Basal A | Sulindac sulfide | COX1/2 | COX | 10581.136 | uM | inf | inf | 0.3918 | 0.3918 | 0.0000 | 0.1575 | 0.4199 | 0.8342 | |
600MPE | HR+ | Luminal | PS-1145 | IKK | NFKB | 5898.065 | uM | inf | inf | 0.9898 | 0.9898 | 0.0000 | 0.1430 | 0.0000 | 0.6845 | |
600MPE | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 5899.094 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0167 | -0.1754 | 1.0334 | |
184A1 | NM | Basal | JNK-IN-5A | JNK | JNK | 12509.168 | uM | inf | 0.95387 | 0.3859 | 0.6171 | 4.9990 | 0.1487 | 0.7274 | 1.3516 | |
600MPE | HR+ | Luminal | Purvalanol A | CDK1 | CDK | 5898.067 | uM | inf | inf | 0.8837 | 0.8837 | 0.0000 | 0.0867 | 0.1356 | 0.6532 | |
600MPE | HR+ | Luminal | GM6001 | MMP | MMP | 5898.096 | uM | inf | inf | 0.8794 | 0.8794 | 0.0000 | 0.0460 | -0.0341 | 0.6718 | |
AU565 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 5900.085 | uM | inf | inf | 0.5199 | 0.5199 | 0.0000 | 0.0667 | 0.2964 | 2.6391 | |
184A1 | NM | Basal | Cetuximab | EGFR | ErbB | 7787.018 | uM | inf | inf | 0.4652 | 0.4652 | 0.0000 | 0.3838 | -0.0013 | 0.3791 | |
AU565 | HER2amp | Luminal | AG1024 | IGF1R | RTK | 5901.066 | uM | inf | 7.61680 | 0.8636 | 0.8635 | 4.6384 | 0.0208 | 0.8425 | 1.9445 | |
21NT | HER2amp | - | Ribavirin | 15383.211 | uM | inf | inf | 1.0074 | 1.0074 | 0.0000 | 0.0469 | 0.0000 | 1.0341 | |||
BT-474 | HER2amp | Luminal | TCS PIM-1 1 | Pim kinase | PIM | 12178.135 | uM | inf | inf | 0.9217 | 0.9217 | 0.0000 | -0.0119 | 0.2808 | 0.5524 | |
BT-474 | HER2amp | Luminal | TCS PIM-1 1 | Pim kinase | PIM | 12056.135 | uM | inf | inf | 0.7081 | 0.7081 | 0.0000 | 0.1158 | 0.4107 | 0.9361 |